ArticleJAMA network open2021
Comparison of 1-Year Health Care Costs and Use Associated With Open vs Robotic-Assisted Radical Prostatectomy.
Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Strategies to improve cost effectiveness of robotic assisted laparoscopic radical prostatectomy in emerging economies.Journal of robotic surgery · 2023Pooled it
- Systematic literature review of cost-effectiveness analyses of robotic-assisted radical prostatectomy for localised prostate cancer.BMJ open · 2022Pooled it
- Function drives 1-year decision regret in radical prostatectomy: a multicentre prospective study.BJU international · 2026Article
- The Evolution of Nerve-Sparing Radical Prostatectomy: Mechanisms of Injury, Economic Impact, and the Potential Value of Intraoperative Nerve Visualization.Journal of clinical medicine · 2026Review
- [First cohort: Robotic radical prostatectomy at the Mexican Institute for Social Security].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Robotics in Interventional Oncology: A Call to Arms?Current oncology reports · 2026Review
- Prospective Evaluation of Ocular Anterior Segment Morphology Changes in the Steep Trendelenburg Position During Robotic-Assisted Laparoscopic Prostatectomy.Journal of clinical medicine · 2026Article
- Medicare Reimbursement Trends in Zenker's Diverticulectomy.Laryngoscope investigative otolaryngology · 2025Article
- Impact of non-surgical OR time on efficiency and costs with Hugo™ RAS.Journal of robotic surgery · 2025Article
- Article
- Robot-assisted approach versus open surgery and conventional laparoscopy for radical prostatectomy for prostate cancer: a micro-costing study.Health economics review · 2025Article
- Frontiers and hotspots of 3D technology in prostatectomy from 1999 to 2024: a bibliometric analysis and visualization.Gland surgery · 2025Article
- Adverse In-Hospital Outcomes Following Robot-Assisted vs. Open Radical Prostatectomy in Quadragenarians.Cancers · 2025Article
- Economic Evaluation of Robotic-assisted Radical Prostatectomy: A Systematic Review and Meta-analysis.European urology open science · 2025Review
- Article
- Surgical Preferences and Fears: Misconceptions about Robotic-Assisted Surgery.Urologia internationalis · 2025Article
- Cost analysis of new robotic competitors: a comparison of direct costs for initial hospital stay between Da Vinci and Hugo RAS for radical prostatectomy.Journal of robotic surgery · 2024Article
- New technology in prostate cancer and financial toxicity.Urologic oncology · 2023Review
- Embracing robotic surgery in low- and middle-income countries: Potential benefits, challenges, and scope in the future.Annals of medicine and surgery (2012) · 2022Review
- Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: With the current patterns of adoption and use of robotic surgery and improvement in the overall survival of patients with prostate cancer, it is important to evaluate the immediate and long-term cost implications of treatments for patients with prostate cancer. Objective: To compare health care costs and use 1 year after open radical prostatectomy (ORP) vs robotic-assisted radical prostatectomy (RARP). Design, Setting, and Participants: This retrospective cohort study used a US commercial claims database from January 1, 2013, to December 31, 2018. A total of 11 457 men aged 18 to 64 years who underwent inpatient radical prostatectomy for prostate cancer and were continuously enrolled with medical and prescription drug coverage from 180 days before to 365 days after inpatient prostatectomy were identified. An inverse probability of treatment weighting analysis was performed to examine the differences in costs and use of health care services by surgical modality. Data analysis was conducted from September 2019 to July 2020. Exposures: Type of surgical procedure: ORP vs RARP. Main Outcomes and Measures: Three outcomes within 1 year after the inpatient prostatectomy were investigated: (1) total health care costs, including reimbursement paid by insurers and out of pocket by patients; (2) health care use, including inpatient readmission, emergency department, hospital outpatient, and office visits; and (3) estimated days missed from work due to health care use. Results: Of the 11 457 patients who underwent inpatient prostatectomy, 1604 (14.0%) had ORP and 9853 (86.0%) had RARP and most patients (8467 [73.9%]) were aged 55 to 64 years. Compared with patients who underwent ORP, those who received RARP had a higher cost at the index hospitalization (mean difference, $2367; 95% CI, $1821-$2914; P < .001), but similar total cumulative costs were observed within 180 days (mean difference, $397; 95% CI, -$582 to $1375; P = .43) and 1 year after discharge (-$383; 95% CI, -$1802 to $1037; P = .60). One-year postdischarge health care use was significantly lower in the RARP compared with ORP group for mean numbers of emergency department visits (-0.09 visits; 95% CI, -0.11 to -0.07 visits; P < .001) and hospital outpatient visits (-1.5 visits; -1.63 to -1.36 visits; P < .001). The reduction in use of health care services among patients who underwent RARP translated into additional savings of $2929 (95% CI, $1600-$4257; P < .001) and approximately 1.69 fewer days (95% CI, 1.49-1.89 days; P < .001) missed from work for health care visits. Conclusions and Relevance: Total cumulative cost in this study was similar between ORP and RARP 1 year post discharge; this finding suggests that lower postdischarge health care use after RARP may offset the higher costs during the index hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.